Pharmacogenomics of Orofacial Pain Management (R01)

The summary for the Pharmacogenomics of Orofacial Pain Management (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pharmacogenomics of Orofacial Pain Management (R01): The goal of this funding opportunity announcement (FOA) is to encourage research on the genetic basis of variability in therapeutic drug responses and adverse events in individuals with painful conditions of the dental, and orofacial region. The objectives are to determine the role of genetic variability in pharmacokinetics, pharmacodynamics, and drug toxicities that contribute to and predict the clinical outcomes of analgesic treatment of individuals with acute and chronic pain conditions. Delineation of genetic variation in drug and neurotransmitter metabolizing enzymes and transporters, drug target molecules such as enzymes and receptors, and associated post-receptor intracellular signaling pathway molecules is an important outcome of this FOA. Identification of key molecular signatures that are predictive of a therapeutic response is a second objective. Clinical and basic science researchers are encouraged to form multidisciplinary teams to effectively address the goals of this FOA. The ability to categorize individuals who differ in their responses to analgesic therapy will aid health care providers in their ability to prescribe the best treatments for acute and chronic pain patients with a personalized/ precision approach. Although this FOA is focused on orofacial pain, it also may serve as a catalyst for the pain research community to explore new pharmacogenomics studies in chronic pain conditions that overlap with temporomandibular joint disorder.

Federal Grant Title:	Pharmacogenomics of Orofacial Pain Management (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DE-16-001
Type of Funding:	Grant
CFDA Numbers:	93.121
CFDA Descriptions:	Oral Diseases and Disorders Research
Current Application Deadline:	Jun 24, 2015
Original Application Deadline:	Jun 24, 2015
Posted Date:	Jan 8, 2015
Creation Date:	Jan 8, 2015
Archive Date:	Jul 25, 2015
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
For profit organizations other than small businesses
Special district governments
State governments
City or township governments
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
County governments
Public and State controlled institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Private institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-16-001.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed); • Collaborative Science to Achieve Disruptive Innovations in Dental, Oral and Craniofacial (...; • HEAL Initiative: INTERACT INTEgRAtive Back Pain Longitudinal Cohort Teams (UC2 Clinical Tr...; • NIDCR Mentored Career Development Award to Promote Broad Participation in Research (K01 In...; • HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies): Chronic Pain Pro...; • Epidemiological and Behavioral Research in Oral Health; • Metagenomic Analyses of the Oral Microbiome; • Phase Iii Clinical Trials in Oral Infectious Diseases
More Grants from the National Institutes of Health: • Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed); • Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed); • Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Inc...; • Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Tri...; • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed...